Comparative Pharmacology
Head-to-head clinical analysis: CORSYM versus NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORSYM versus NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE.
CORSYM vs NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenylephrine is a selective α1-adrenergic receptor agonist causing vasoconstriction; chlorpheniramine is a first-generation antihistamine that competitively inhibits histamine at H1 receptors.
Naphazoline is an alpha-adrenergic receptor agonist that causes vasoconstriction of conjunctival blood vessels, reducing redness and edema. Pheniramine is a histamine H1-receptor antagonist that blocks the effects of histamine, reducing itching and allergic symptoms.
Adults: 100 mg orally once daily, taken with water at least 1 hour before meals. Maximum dose 100 mg/day.
1-2 drops or sprays in each nostril every 4-6 hours as needed, not to exceed 5-7 days
None Documented
None Documented
The terminal elimination half-life for hydrocodone from the CORSYM formulation is approximately 8-10 hours, reflecting the extended-release profile. This allows for twice-daily dosing. Hydrocodone's half-life in immediate-release forms is about 3-4 hours, so the polistirex complex prolongs absorption. Chlorpheniramine has a half-life of about 20-24 hours in adults, but in the polistirex formulation, its half-life is extended to approximately 18-22 hours, supporting once-daily dosing for the antihistamine component.
Naphazoline: Terminal elimination half-life approximately 2-3 hours; clinical effects may persist longer due to local vasoconstriction. Pheniramine: Terminal elimination half-life approximately 14-16 hours; appropriate for twice-daily dosing.
CORSYM (hydrocodone polistirex and chlorpheniramine polistirex) is an extended-release formulation. Hydrocodone is metabolized primarily in the liver via CYP3A4 and CYP2D6 to norhydrocodone, hydromorphone, and other metabolites. Excretion is predominantly renal (about 90%) as unchanged drug and metabolites, with approximately 10% excreted in feces via biliary elimination. Chlorpheniramine is metabolized in the liver and excreted renally as metabolites (about 70-80%) and unchanged drug (about 10-20%), with minor fecal excretion.
Naphazoline: Renal excretion of unchanged drug and metabolites accounts for >80% of elimination. Pheniramine: Renal excretion of unchanged drug and metabolites accounts for >90% of elimination, with <5% biliary/fecal elimination.
Category C
Category C
Antihistamine/Decongestant
Ophthalmic Antihistamine/Decongestant